A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Redefining sensor performance with advanced physical AI and signal processing.
Updated
January 8, 2026 6:32 PM
.jpg)
Robot with human features, equipped with a visual sensor. PHOTO: UNSPLASH
Atomathic, the company once known as Neural Propulsion Systems, is stepping into the spotlight with a bold claim: its new AI platforms can help machines “see the invisible”. With the commercial launch of AIDAR™ and AISIR™, the company says it is opening a new chapter for physical AI, AI sensing and advanced sensor technology across automotive, aviation, defense, robotics and semiconductor manufacturing.
The idea behind these platforms is simple yet ambitious. Machines gather enormous amounts of signal data, yet they still struggle to understand the faint, fast or hidden details that matter most when making decisions. Atomathic says its software closes that gap. By applying AI signal processing directly to raw physical signals, the company aims to help sensors pick up subtle patterns that traditional systems miss, enabling faster reactions and more confident autonomous system performance.
"To realize the promise of physical AI, machines must achieve greater autonomy, precision and real-time decision-making—and Atomathic is defining that future," said Dr. Behrooz Rezvani, Founder and CEO of Atomathic. "We make the invisible visible. Our technology fuses the rigor of mathematics with the power of AI to transform how sensors and machines interact with the world—unlocking capabilities once thought to be theoretical. What can be imagined mathematically can now be realized physically."
This technical shift is powered by Atomathic’s deeper mathematical framework. The core of its approach is a method called hyperdefinition technology, which uses the Atomic Norm and fast computational techniques to map sparse physical signals. In simple terms, it pulls clarity out of chaos. This enables ultra-high-resolution signal visualization in real time—something the company claims has never been achieved at this scale in real-time sensing.
AIDAR and AISIR are already being trialled and integrated across multiple sectors and they’re designed to work with a broad range of hardware. That hardware-agnostic design is poised to matter even more as industries shift toward richer, more detailed sensing. Analysts expect the automotive sensor market to surge in the coming years, with radar imaging, next-gen ADAS systems and high-precision machine perception playing increasingly central roles.
Atomathic’s technology comes from a tight-knit team with deep roots in mathematics, machine intelligence and AI research, drawing talent from institutions such as Caltech, UCLA, Stanford and the Technical University of Munich. After seven years of development, the company is ready to show its progress publicly, starting with demonstrations at CES 2026 in Las Vegas.
Suppose the future of autonomy depends on machines perceiving the world with far greater fidelity. In that case, Atomathic is betting that the next leap forward won’t come from more hardware, but from rethinking the math behind the signal—and redefining what physical AI can do.